Cargando…
Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630.
Ten previously untreated postmenopausal women with metastatic breast cancer, none of whom had received prior systemic therapy, were treated with the luteinising hormone releasing hormone (LHRH) analogue D-Ser(But)6, Azgly10-LHRH (ICI 118630). Two obtained an objective partial remission, one in bone...
Autores principales: | Plowman, P. N., Nicholson, R. I., Walker, K. J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1986
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001583/ https://www.ncbi.nlm.nih.gov/pubmed/2948537 |
Ejemplares similares
-
Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.
por: Nicholson, R. I., et al.
Publicado: (1979) -
The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer.
por: Williams, M. R., et al.
Publicado: (1986) -
Response in post-menopausal patients on ICI 118630.
por: Robertson, J. F., et al.
Publicado: (1987) -
Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects.
por: Crighton, I. L., et al.
Publicado: (1989) -
Circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients.
por: Secreto, G., et al.
Publicado: (1983)